MedTrace Logo

Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects

NCT03082768 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-03-06

No results posted yet for this study

Summary

The overall goal of this protocol is to evaluate \[18F\]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[18F]MNI-968

Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.

Sponsors & Collaborators

  • Molecular NeuroImaging

    lead OTHER

Principal Investigators

  • Jennifer Madonia, PA-C · Molecular NeuroImaging, LLC

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2018-03-01
Completion
2018-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03082768 on ClinicalTrials.gov